Neogen Other Operating Expenses Over Time
| NEOG Stock | USD 14.14 0.03 0.21% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neogen Performance and Neogen Correlation. Neogen |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neogen. If investors know Neogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share (0.11) | Revenue Per Share 4.212 | Quarterly Revenue Growth (0.05) | Return On Assets 0.0085 |
The market value of Neogen is measured differently than its book value, which is the value of Neogen that is recorded on the company's balance sheet. Investors also form their own opinion of Neogen's value that differs from its market value or its book value, called intrinsic value, which is Neogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neogen's market value can be influenced by many factors that don't directly affect Neogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Operating Expenses Analysis
Compare Neogen and related stocks such as Qiagen NV, Olink Holding AB, and Aclaris Therapeutics Other Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QGEN | 32.3 M | 1.1 B | 1.1 B | 1.2 B | 1.2 B | 1.1 B | 1.2 B | 1.3 B | 1.2 B | 1.2 B | 1.3 B | 1.6 B | 1.6 B | 1.5 B | 827.1 M |
| ACRS | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 8.5 M | 20.7 M | 48.6 M | 74.1 M | 145.5 M | 96.8 M | 57.4 M | 72.1 M | 114.9 M | 128.6 M | 77.2 M |
| IQV | 3.5 B | 3.9 B | 4.5 B | 4.6 B | 4.9 B | 5.1 B | 6 B | 8.9 B | 9.6 B | 10.2 B | 10.6 B | 12.5 B | 12.6 B | 13 B | 8.6 B |
| MEDP | 214 M | 214 M | 214 M | 214 M | 284.8 M | 329.2 M | 369.1 M | 371.3 M | 603.5 M | 733.7 M | 758.9 M | 943.8 M | 1.2 B | 1.5 B | 1.6 B |
| ICLR | 49.3 M | 906.5 M | 1 B | 1.2 B | 1.3 B | 1.3 B | 1.3 B | 1.4 B | 2.2 B | 2.4 B | 2.4 B | 4.9 B | 6.9 B | 7.2 B | 7.5 B |
| SHC | 580.2 M | 580.2 M | 580.2 M | 580.2 M | 580.2 M | 580.2 M | 580.2 M | 580.2 M | 580.2 M | 588.9 M | 612.1 M | 674.7 M | 755.3 M | 772.6 M | 730.4 M |
| RDNT | 98.1 M | 571.4 M | 600.7 M | 657.5 M | 661.9 M | 768.9 M | 842.4 M | 869.2 M | 940.4 M | 1.1 B | 1 B | 1.2 B | 1.4 B | 1.5 B | 1.6 B |
| MYGN | 15.5 M | 244.3 M | 315.7 M | 385.2 M | 503.8 M | 588.9 M | 587 M | 722 M | 715.1 M | 842.4 M | 831.5 M | 879.3 M | 802.1 M | 1 B | 1.1 B |
| FONR | 11 M | 32.2 M | 41.6 M | 56.2 M | 56.2 M | 59 M | 58.9 M | 61.8 M | 65.1 M | 72 M | 72.8 M | 75.6 M | 83.9 M | 86.3 M | 54.7 M |
| XGN | 8.4 M | 8.4 M | 8.4 M | 10.9 M | 23.5 M | 28.6 M | 34.7 M | 34.7 M | 37.3 M | 49.7 M | 57.2 M | 72.4 M | 86.1 M | 75.4 M | 48.4 M |
| SERA | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 18 M | 35.5 M | 45.9 M | 40.1 M | 34.3 M |
| BNR | 232 M | 232 M | 232 M | 232 M | 232 M | 232 M | 232 M | 232 M | 370.3 M | 550.8 M | 842.3 M | 1.3 B | 1.5 B | 1.2 B | 950.8 M |
Neogen and related stocks such as Qiagen NV, Olink Holding AB, and Aclaris Therapeutics Other Operating Expenses description
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Neogen. It is also known as Neogen overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.My Equities
My Current Equities and Potential Positions
Check out Neogen Performance and Neogen Correlation. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Neogen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.